Register Login

Passage Bio Inc (PASG)

  • Event
  • Feb. 24, 2023, 12:00 UTC

(10% Negative) PASSAGE BIO, INC. (PASG) Announces Delay in patients Trials for GM1 gangliosidosis (GM1) Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 4, 2025, 6:15 a.m.

    📋 PASSAGE BIO, INC. (PASG) - Clinical Trial Update

    Filing Date: 2023-02-24

    Accepted: 2023-02-24 07:00:19

    Event Type: Clinical Trial Update

    Event Details:

    Passage Bio Inc (PASG) Announces Clinical Trial Update Passage Bio Inc (PASG) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients
    • Diseases/Conditions: GM1 gangliosidosis (GM1), our Imagine-1 s
    • Clinical Stage: Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: CNS
    • Updated Timeline: February 24, 2023

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Passage Bio Inc
    • CIK: 0001787297
    • Ticker Symbol: PASG
    • Period End Date: 2023-02-24
    • Document Type: 8-K

Search

News categories